(QDEL) Quidel - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US74838J1016
QDEL: Tests, Instruments, Reagents, Kits, Assays, Diagnostics
QuidelOrtho Corporation (NASDAQ: QDEL) is a leader in diagnostic testing solutions, operating across four distinct business units: Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics. The Labs division specializes in clinical chemistry and immunoassay instruments, providing critical data for patient health evaluation and disease management. Their Transfusion Medicine unit ensures compatibility and safety in blood transfusions and donor screening. The Point-of-Care segment offers rapid testing solutions for diverse healthcare settings, while Molecular Diagnostics focuses on innovative PCR and syndromic testing.
With a market cap of approximately $2.9 billion, QuidelOrtho is strategically positioned in the diagnostics industry, offering a broad range of testing solutions. Their products are distributed directly and through a global network, reaching physician offices, hospitals, and clinical laboratories. This extensive distribution underscores their commitment to accessibility and reliability in healthcare diagnostics.
QuidelOrthos financials, including a forward P/E of 17.27 and P/S of 1.04, highlight their potential for growth and profitability. Their global presence in North America, Europe, and other regions further solidifies their market reach. Established in 1979 and headquartered in San Diego, QuidelOrtho continues to innovate, making it a notable player in the diagnostics sector.
Additional Sources for QDEL Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
QDEL Stock Overview
Market Cap in USD | 2,695m |
Sector | Healthcare |
Industry | Medical Devices |
GiC Sub-Industry | Health Care Supplies |
IPO / Inception | 1991-02-01 |
QDEL Stock Ratings
Growth 5y | -56.4% |
Fundamental | -45.8% |
Dividend | 0.0% |
Rel. Strength Industry | -24.6 |
Analysts | 3.63/5 |
Fair Price Momentum | 30.01 USD |
Fair Price DCF | 28.44 USD |
QDEL Dividends
No Dividends PaidQDEL Growth Ratios
Growth Correlation 3m | -70.1% |
Growth Correlation 12m | -6.3% |
Growth Correlation 5y | -93.3% |
CAGR 5y | -13.39% |
CAGR/Max DD 5y | -0.15 |
Sharpe Ratio 12m | -1.83 |
Alpha | -30.59 |
Beta | 0.38 |
Volatility | 48.36% |
Current Volume | 856k |
Average Volume 20d | 739.1k |
As of March 16, 2025, the stock is trading at USD 36.12 with a total of 855,971 shares traded.
Over the past week, the price has changed by -11.47%, over one month by -10.97%, over three months by -17.61% and over the past year by -23.93%.
Probably not. Based on ValueRay Fundamental Analyses, Quidel (NASDAQ:QDEL) is currently (March 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -45.84 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of QDEL as of March 2025 is 30.01. This means that QDEL is currently overvalued and has a potential downside of -16.92%.
Quidel has received a consensus analysts rating of 3.63. Therefor, it is recommend to hold QDEL.
- Strong Buy: 2
- Buy: 2
- Hold: 3
- Sell: 1
- Strong Sell: 0
According to ValueRays Forecast Model, QDEL Quidel will be worth about 32.4 in March 2026. The stock is currently trading at 36.12. This means that the stock has a potential downside of -10.27%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 51.1 | 41.6% |
Analysts Target Price | 51.1 | 41.6% |
ValueRay Target Price | 32.4 | -10.3% |